Gliptin Repurposing for COVID-19

Matthew Groves, Alexander Domling, Angel Jonathan Ruiz Moreno, Atilio Reyes Romero, Constantinos Neochoritis, Marco Velasco-Velázquez

Submitted date: 10/04/2020 • Posted date: 15/04/2020
Licence: CC BY-NC-ND 4.0


De novo drug discovery of any therapeutic modality (e.g. antibodies, vaccines or small molecules) historically takes years from idea/preclinic to the market and it is therefore not a short-term solution for the current SARS-CoV-2 pandemic. Therefore, drug repurposing – the discovery novel indication areas for already approved drugs - is perhaps the only approach able to yield a short term relieve. Here we describe computational screening results suggesting that certain members of the drug class of gliptins are inhibitors of the two SARS-CoV-2 proteases 3CLpro and PLpro. The oral bioavailable antidiabetic drug class of gliptins are safe and have been introduced clinically since 2006 and used by millions of patients since then. Based on our repurposing hypothesis the nitrile containing gliptins deserve further investigation as potential anti-COVID19 drugs.
Gliptin repurposing for COVID-19

Angel Jonathan Ruiz Moreno,1,2, 5 Atilio Reyes Romero,1 Constantinos Neochoritis,3,6 Matthew Groves,1 Marco Velasco-Velázquez,2, 5 Alexander Dömling1,3,4,*

1 Department of Drug Design, University of Groningen, The Netherlands
2 Departamento de Farmacología y Unidad Periférica de Investigación en Biomedicina Traslacional, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM). Ciudad de México, México.
3 Telesis Pharma, Groningen, The Netherlands
4 FORTH, Institute of Molecular Biology and Biotechnology, Crete, Greece
5 Programa de Doctorado en Ciencias Biomédicas, UNAM. Ciudad de México, México.
6 University of Crete, Department of Chemistry, Greece.

Background

De novo discovery of any therapeutic (e.g. antibodies, vaccines or small molecules) takes years to move from idea/preclinic to market release and is not a short-term solution for the current SARS-CoV-2 pandemic. Therefore, drug repurposing – the discovery of novel indication areas for already approved drugs is perhaps the only approach able to yield a short-term solution.

Methods

In order to repurpose drugs as potential inhibitors of SARS-CoV-2 proteases 3CLpro and PLpro, we performed a computational screening using the oral bioavailable antidiabetic drug class of gliptins as candidates.

Results

The orally bioavailable antidiabetic drug class of gliptins is safe and has been clinically available (and used by millions of patients) since 2006. Based on our repurposing hypothesis and our computational docking we predict the nitrile containing gliptins to inhibit the SARS-CoV-2 proteases 3CLpro and PLpro. As a result, nitrile containing gliptins deserve further investigation as potential anti-COVID19 drugs.

In December 2019, a novel coronavirus (SARS-CoV-2 the cause of the disease named COVID-19) was found in Wuhan, China.1 Human-to-human transmission has occurred among close contacts.2 As of 30 March 2020, there have been over 700,000 reported cases with over 30,000 deaths for the SARS-CoV-2 pandemic worldwide. However, there are currently no effective medications against SARS-CoV-2.

De novo drug discovery historically takes years from idea/preclinic to the market, independently of the nature of the drug (e.g. small molecule, antibody, vaccine). Thus, this strategy is not a short-term solution for the current pandemic. Drug repurposing aims to discover novel indications for already
approved drugs. The overwhelming advantage of drug repurposing is the much faster clinical approval, due to already extensive knowledge of the physicochemical properties and behavior of the drug in humans. Therefore, many groups have pursued a drug repurposing approach. This has led to several promising drugs which are currently tested for COVID-19 in humans, including Favipiravir, Remdesivir, HIV protease inhibitors, chloroquine or Tozilizumab. So far, however, none showed more than promising activity based on low numbers of patients per trial. Additionally, a combination of Lopinavir and Ritonavir (Kaletra®) – effective for HIV infection – failed in ~200 severe COVID-19 cases in China. Lopinavir and Ritonavir did not show any benefit over the current standard therapy. Clearly, additional drug repurposing hypotheses need to be tested.

In our search for drugs potentially inhibiting the replication of the SARS-CoV-2 we concentrated on compounds inhibiting the proteases. Both the virus encoded proteases, including the 3C-like protease (3CLpro) and Papain-like proteinase (PLpro), are highly conserved among CoVs and are involved in the essential processing of the viral polyprotein in a coordinated manner. Therefore, they represent important drug targets. 3CLpro cleaves the C-terminus of replicase polyprotein at 11 sites. Recently, the Å resolution 3D X-ray structure was reported of the 3CLpro covalently bound to a peptidomimetic acrylester (PDB ID 6LU7). PLpro is responsible for the cleavages located at the N-terminus of the replicase polyprotein and has other important functions during the viral replication cycle. Thus, we concentrated our investigations on drug classes with a reactive warhead potentially reacting with the 3CLpro active site Cys145 and/or PLpro active site Cys112, respectively.

Gliptins are a class of oral hypoglycemics that inhibit the enzyme dipeptidyl peptidase-4 (DPP-4), a serine protease that rapidly inactivates incretin hormones in plasma. They are widely used as drugs to treat diabetes mellitus type 2. The first compound - sitagliptin - received market approval in 2006. Since then many new gliptins were introduced (Fig. 1A, B). Mechanistically, gliptins can be divided in two classes, covalent and non-covalent inhibitors. The nitrile containing gliptins make a covalent bond with the active site Ser630 of DPP-4 (Fig. 1C). Nitrile containing gliptins include Saxagliptin, Vildagliptin, Bisegliptin, Trelagliptin, Anagliptin, Melogliptin, and Denaagliptin (Fig. 1B). We hypothesized that nitrile containing gliptins might be potential repurposing candidates given that cysteines are well known to react with nitriles to form covalent adducts in a similar way as serines (Fig. 1D). For example arylnitriles have been described as cysteine protease inhibitors. To form stable adducts the covalent imidate is often stabilized by a hydrogen bonding network to the receptor. In the case of Vildagliptin, the imidate NH forms hydrogen bondings to the Tyr547 OH and an adjacent water molecule (Figure 1C).
Figure 1. Antidiabetic gliptins as potential COVID-19 repurposing drugs. A) Marketed or late stage non-covalent DPP-4 inhibitors. B) Marketed or late stage covalent DPP-4 inhibitors with electrophile nitrile circled in red. C) Example (PDB ID 6B1E) of Vildagliptin (cyan sticks) covalently bound to 3CLpro Ser630 (grey sticks) and the imine group stabilized by a hydrogen bond to Tyr547 (grey sticks) and a water molecule (red ball). D) Mechanistic similarity of nucleophilic serine and cysteine addition to an electrophilic nitrile.

Methods In order to evaluate the potential of the nitrile containing gliptins as 3CLpro and PLpro inhibitors, we performed covalent docking using GOLD and CovDock software. The potential implication of gliptins binding to the were analyzed by minimizing the complexes comprising best docking poses using the MAB force field (detailed methods in SI). For SARS-CoV-2 3CLpro (PDB ID 6LU7), the catalytic Cys145 was used as docking site. For SARS-CoV-2 PLpro there is no crystal structure yet available. However, the PLpro from SARS-CoV-2 shows an high sequence identity (83%) with PLpro from SARS-CoV (Fig. S1). Specifically, in the near vicinity of the active site and binding site of inhibitors they are identical. Thus, we decided to use SARS-CoV PLpro (PDB ID 2FE8) Cys112 as binding site for our docking experiments. Additionally, the cooperative interaction networks were evaluated for the best poses from GOLD and CovDock docking using Scorpion software.

Results and discussion Docking scores and cooperative binding network analysis showed higher values for all gliptins against 3CLpro (Tables S2 and Fig. S2B), suggesting a higher affinity for the gliptins rather than PLpro (Table S1 and Fig. S2A). Vildagliptin was identified as the best dual action candidate for both 3CLpro and PLpro (Fig. 2A, B). On the other hand, Denagliptin and Anaglitin were identified as the best candidates for 3CLpro and PLpro, respectively. Saxagliptin and secondly Trelagliptin, showed a consensus score value higher against 3CLpro rather than PLpro, indicating a possible higher selectivity for 3CLpro.
However, Melogliptin and Bisegliptin displayed higher consensus score values for PLpro suggesting a possible selectivity for this target. Finally, as stated previously, scoring values for 3CLpro were higher, indicating that selectivity of gliptins against 3CLpro and more importantly against PLpro must be considered carefully.

Docking results showed that by forming the covalent complex with 3CLpro the best compounds (Vildagliptin, Anagliptin, and Denagliptin) were able to form an extended hydrogen bonding network and/or hydrophobic interaction with the His41 (Fig. 2A). Both, Cys145 and His41 are part of the catalytic dyad of different CoV’s main proteases. Additionally, the scores of Vildagliptin, Anagliptin and Denagliptin and His41 were preserved and in some cases enhanced, suggesting that binding of these gliptins could induce and adjust the fit which potentiates the binding and stabilization of these compound into the catalytic site of 3CLpro (Table S4). Therefore, these gliptins could have a direct impact on the protease 3CLpro function, and consequently impact the replication cycle of SARS-CoV-2.

The protease activity of PLpro has been reported to be catalyzed by the dyad Cys112 and His273 or the triad additionally involving Asp287. Interestingly, such inhibitors bind in a cavity next to the catalytic triad but none of them interacts directly with the residues of the catalytic triad, despite proving high potency and selectivity in vitro. All gliptins are predicted to potentially form covalent adducts to SARS-CoV and SARS-CoV-2 proteases through direct interaction with the Cys112 in the catalytic triad where also other reported inhibitors bind (Fig. S5). Amongst the best candidates for PLpro (Anagliptin, Vildaglipti and Melogliptin) (Fig. 2B, Table S3) only Anagliptin is able to form a hydrogen bonding interaction with the His273. However, the three proposed gliptins were able to form an extended network of ligand-receptor interactions, mainly hydrogen bonds and hydrophobic interactions, with the same residues as the reported inhibitors: Gly164, Asp165, and Tyr269. Therefore, our results suggest the formation a stable binding of the nitrile containing gliptins (Fig. S3, S4) and a possible inhibition of PLpro activity.
Figure 2. Covalent docking of the nitrile-gliptins into the SARS-CoV-2 protease 3CLpro (PDB ID 6LU7) and SARS-CoV-1 protease PLpro (PDB ID 2FE8). A, B) Consensus docking scores for the nitrile-gliptins for the two proteases. B, C) Highest scoring poses of the best dual action Vildagliptin in 3CLpro and PLpro with some indicated molecular interactions. The active site cysteines forming the covalent bond are shown in yellow. Insert in D) shows the stabilization of the thioimidate structure through an intramolecular hydrogen bond to the pyrrolidine acyl carbonyl and a H-bond donor pi interaction to the backbone NH of Tyr113.

Gliptin drug safety has been monitored over more than a decade and good tolerance/safety profile of DPP-4 inhibitors has been largely confirmed, importantly including elderly populations.\textsuperscript{18} Gliptins are orally bioavailable, easy to formulate, and can be and are already delivered to millions of people in the form of a pill. They are already manufactured on scale, which is critical in the current pandemic. They are stable at ambient temperature and have a long shelf life. Furthermore, PK/PD is also well established. For example, the plasma half-life of Saxagliptin (~27 h) is much longer than that of Vildagliptin (~2 h) and thus Saxagliptin requires lower therapeutic dosage than Vildagliptin: Saxagliptin is administrated 5 mg once a day, while Vildagliptin is 50 mg twice a day.\textsuperscript{20–22} However nothing is known about PK/PD profile of the different gliptins in the lungs. Based on the hypothetical inhibition mechanism of the viral replication through inhibition of the two essential SARS-CoV-2 proteases and the well-established safety profile a preventative and/or curative application of the selected gliptins is thinkable.

Unfortunately, due to the general shutdown of research and academic laboratories worldwide further studies including protease assays and cell-based virus proliferation assays cannot be performed at this time. The severity of the SARS-CoV-2 pandemic prompted us to publish our preliminary results. We hope that our drug repurposing hypothesis could become the starting point to perform further studies in severely ill COVID-19 patients.
References


Gliptin repurposing for COVID-19

Angel Jonathan Ruiz Moreno,1,2,5 Atilio Reyes Romero,1 Constantinos Neochoritis,3 Matthew Groves,1 Marco Velasco-Velázquez,2,5 Alexander Dömling1,3,4*

1 Department of Drug Design, University of Groningen, The Netherlands
2 Departamento de Farmacología y Unidad Periférica de Investigación en Biomedicina Traslacional, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM). Ciudad de México, México.
3 Telesis Pharma, Groningen, The Netherlands
4 FORTH, Institute of Molecular Biology and Biotechnology, Crete, Greece
5 Programa de Doctorado en Ciencias Biomédicas, UNAM. Ciudad de México, México.

Supporting information

Table of content

201 Virtual screening methodologies ................................................................. 10
202 Consensus score ....................................................................................... 10
203 Table S3 Normalized and consensus score of gliptins against SARS-CoV PLpro .................................................................................. 12
204 Table S4 Normalized and consensus score of gliptins against SARS-CoV-2 3CLpro ................................................................. 12
205 Vildagliptin as study case ............................................................................. 14
206 References .................................................................................................... 16

207 Figure S1 .................................................................................................... S2
208 Virtual screening methodologies ................................................................. S2
209 Consensus score ....................................................................................... S3
210 Table S1 .................................................................................................... S3
211 Table S2 .................................................................................................... S3
212 Figure S2 .................................................................................................... S4
213 Table S3 .................................................................................................... S4
214 Table S4 .................................................................................................... S5
Vildaglptin as study case

Figure S3

Figure S4

Comparison against the non-covalent inhibitor of PLpro of SARS-CoV

Figure S5

References

**Figure S1** Pairwise alignment of SARS-CoV (blue colored, PDB ID: 2FE8) and SARS-CoV-2 (NCBI Reference Sequence: YP_009725299) papain-like proteases (PLpro). The catalytic triad (Cys112, His273 and Asp287) is indicated by a brown stars. Identical residues are framed in blue, non-identical ones are highlighted in yellow while similar residues colored in red. The residues flagging the binding site are purple boxed. Alignment was done with ClustalW and secondary structures elements were created with EsPript 3.0.
Virtual screening methodologies

GOLD

The crystal structures of SARS-CoV-2 3CLpro (PDB ID 6LU7) and SARS-CoV PLpro (PDB ID 2EF8) were used as a receptor and Alogliptin, Anagliptin, Bisegliptin, Denagliptin, Melogliptin, Saxagliptin, Trelagliptin, and Vildagliptin as ligands. Protein were prepared by removing co-crystallized ligand if present, water, and solvent molecules; and adding charges and hydrogens using Chimera 1.14. Isomeric SMILE codes for ligands were retrieved from PubChem and prepared for docking by setting the absolute stereo flags, adding explicit hydrogens and tautomeric states at pH 7.4. 3D coordinates were generated with Standardized 19.20.0 (http://www.chemaxon.com). For the covalent docking, the sulfur atom of the reactive cysteines of the receptors were used as linker to perform the covalent bonding (Cys145 for 3CLpro and Cys112 for PLpro). For each ligand, 50 runs of genetic algorithm for the conformational search were performed and each pose was evaluated employing the PLP Chemscore scoring function.

CovDock

The crystal structures of SARS-CoV-2 3CLpro (PDB ID 6LU7) and SARS-CoV PLpro (PDB ID 2EF8) were prepared by assigning bond orders, hydrogens and protonation state at pH 7.4 with Epik and missing side chains/loops were filled with Prime. Water molecules beyond 5.0 Å and DMSO were removed. Finally, the structures were further refined by assigning the optimal H-bonds orientations with PROPKA3 at pH 7.4 and a restrained minimization was then applied with OPLS_2005 until 0.30 Å RMSD convergence. The 3D-structures and the relative tautomers of the gliptins at pH 7.4 from isomeric smiles were respectively generated with Ligprep (Schrödinger Release 2019-4: LigPrep, Schrödinger, LLC, New York, NY, 2020) and Epik, including the stereoflags at the chiral centers. The docking grid was defined in center of coordinates -14.54 x 46.05 x -38.91 and 20.0 Å of spacing in all directions. Covalent reaction was set as nucleophilic addition to triple bond and docking was run including ligand conformational sampling, rotamer sampling of the protein side chains, and minimization of the pose. A total number of 200 poses were requested employing a cutoff of 2.5 kcal/mol as a restrain. Subsequently, the best poses were selected based on GlideScore value (kcal/mol unit).

Consensus score

For GOLD and CovDock, the cooperativity interaction networks were assessed by Scorpion before and after MAB force field minimization with Moloc. All the figures were rendered with PyMOL (The PyMOL Molecular Graphics System, Version 2.3, Schrödinger, LLC).

<table>
<thead>
<tr>
<th>Compound</th>
<th>CovDock</th>
<th>GOLD</th>
<th>Scorpion_CovDock</th>
<th>Scorpion_GOLD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alogliptin</td>
<td>-2.89</td>
<td>0</td>
<td>7.7</td>
<td>1.2</td>
</tr>
</tbody>
</table>
### Table S2

Final docking scores obtained by CovDock, GOLD, and Scorpion scores calculated from the best poses of gliptins against SARS-CoV-2 3CLpro.

<table>
<thead>
<tr>
<th>Compound</th>
<th>CovDock</th>
<th>GOLD</th>
<th>Scorpion_CovDock</th>
<th>Scorpion_GOLD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alogliptin</td>
<td>-5.92</td>
<td>89,8825</td>
<td>3.4</td>
<td>5.0</td>
</tr>
<tr>
<td>Vildagliptin</td>
<td>-6.48</td>
<td>85,007</td>
<td>6.7</td>
<td>10.1</td>
</tr>
<tr>
<td>Denagliptin</td>
<td>-6.29</td>
<td>90,6431</td>
<td>6.9</td>
<td>11.6</td>
</tr>
<tr>
<td>Anagliptin</td>
<td>-6.23</td>
<td>94,6538</td>
<td>5.7</td>
<td>6.3</td>
</tr>
<tr>
<td>Melogliptin</td>
<td>-6</td>
<td>87,8583</td>
<td>5</td>
<td>3.3</td>
</tr>
<tr>
<td>Bisegliptin</td>
<td>-5.74</td>
<td>80,1911</td>
<td>2.8</td>
<td>6.2</td>
</tr>
<tr>
<td>Trelagliptin</td>
<td>-5.61</td>
<td>91,2258</td>
<td>5.8</td>
<td>3.1</td>
</tr>
<tr>
<td>Saxagliptin</td>
<td>-5.45</td>
<td>92,5049</td>
<td>6.9</td>
<td>7.4</td>
</tr>
</tbody>
</table>
Figure S2 Normalized docking scores for papain-like protease (A) and coronavirus main protease (B).

Table S3 Normalized and consensus score of gliptins against SARS-CoV PLpro.

<table>
<thead>
<tr>
<th>Compound</th>
<th>CovDock</th>
<th>GOLD</th>
<th>Scorpion_CovDock</th>
<th>Scorpion_GOLD</th>
<th>Consensus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alogliptin</td>
<td>0,8</td>
<td>0</td>
<td>0,74</td>
<td>0</td>
<td>1,54</td>
</tr>
<tr>
<td>Denagliptin</td>
<td>1</td>
<td>0,19</td>
<td>0,98</td>
<td>0,84</td>
<td>3</td>
</tr>
<tr>
<td>Anagliptin</td>
<td>0,82</td>
<td>1</td>
<td>0,73</td>
<td>0,79</td>
<td>3,34</td>
</tr>
<tr>
<td>Bisegliptin</td>
<td>0,81</td>
<td>0,8</td>
<td>0,28</td>
<td>0,79</td>
<td>2,67</td>
</tr>
<tr>
<td>Melogliptin</td>
<td>0,7</td>
<td>0,89</td>
<td>1</td>
<td>0,58</td>
<td>3,17</td>
</tr>
<tr>
<td>Vildagliptin</td>
<td>0,62</td>
<td>0,88</td>
<td>0,69</td>
<td>1</td>
<td>3,20</td>
</tr>
<tr>
<td>Saxagliptin</td>
<td>0</td>
<td>0,33</td>
<td>0</td>
<td>0,27</td>
<td>0,59</td>
</tr>
<tr>
<td>Trelagliptin</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0,51</td>
<td>0,51</td>
</tr>
</tbody>
</table>

Table S4 Normalized and consensus score of gliptins against SARS-CoV-2 3CLpro.

<table>
<thead>
<tr>
<th>Compound</th>
<th>CovDock</th>
<th>GOLD</th>
<th>Scorpion_CovDock</th>
<th>Scorpion_GOLD</th>
<th>Consensus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alogliptin</td>
<td>0,46</td>
<td>0,67</td>
<td>0,15</td>
<td>0,22</td>
<td>1,5</td>
</tr>
<tr>
<td>Denagliptin</td>
<td>0,82</td>
<td>0,72</td>
<td>1</td>
<td>1</td>
<td>3,54</td>
</tr>
<tr>
<td>Anagliptin</td>
<td>0,76</td>
<td>1</td>
<td>0,71</td>
<td>0,38</td>
<td>2,84</td>
</tr>
<tr>
<td>Bisegliptin</td>
<td>0,28</td>
<td>0</td>
<td>0</td>
<td>0,36</td>
<td>0,65</td>
</tr>
<tr>
<td>Melogliptin</td>
<td>0,53</td>
<td>0,53</td>
<td>0,54</td>
<td>0,02</td>
<td>1,62</td>
</tr>
<tr>
<td>Vildagliptin</td>
<td>1</td>
<td>0,33</td>
<td>0,95</td>
<td>0,82</td>
<td>3,11</td>
</tr>
<tr>
<td>Saxagliptin</td>
<td>0</td>
<td>0,85</td>
<td>1</td>
<td>0,51</td>
<td>2,36</td>
</tr>
<tr>
<td>Trelagliptin</td>
<td>0,16</td>
<td>0,76</td>
<td>0,73</td>
<td>0</td>
<td>1,65</td>
</tr>
</tbody>
</table>
Vildagliptin as study case

SARS-CoV-2 3CLpro

The best Vildagliptin poses of CovDock (Fig. S3A) and GOLD (Fig. S3B) in 3CLpro form a covalent bond with Cys145. The adamantyl group interacts with His41, Met49, Gly143, Cys145, His163, His164, Met165 side chains through a wide network of Van der Walls interactions (Fig. S3). However, the CovDock pose has one extra hydrogen bond - \( \pi \) stacking interaction with the CO backbone moiety of Arg188 while in the GOLD pose was observed an extra Van der Walls interaction with Gln189 side chain and one hydrogen bond/\( \pi \) stacking with NH moiety of Cys112. Both poses show that the imidate group is stabilized by dipolar interaction with carbonyl moiety of Gly143. Additionally, many of these interactions were also observed in the recently published non-covalent designed alpha-ketoamide inhibitor of 3CLpro. On the other hand, considerable modification to the backbone of the protease domain of 3CLpro (residues 10-99) were observed because of the binding of Vildagliptin. These findings together could provide evidence suggesting Vildagliptin, and other reported gliptins as potential inhibitors of SARS-CoV-2 main protease.

Figure S3 Molecular interactions of Vildagliptin with SARS-CoV-2 3CLpro and induced fit. The figure shows the molecular interactions of best pose of CovDock (A – green sticks-) and GOLD (B – cyan sticks-). Van der Walls interactions are shown as yellow lines, hydrogen bond/\( \pi \) stacking in magenta, and dipolar interactions in cyan. Larger displacements between the apo-3CLpro backbone (white) and Vildagliptin-3CLpro complexes after MAB minimizations were observed in the protease domain of 3CLpro (orange sections).
Whereas CovDock (Fig. S4A) and GOLD (Fig. S4B), they predicted Van der Walls interactions between the adamantyl group of Vinagliptin and Tyr269, His273, and Tyr274 side chains in addition to the covalent bond between the nitrile and the Cys112. However, in the case of CovDock, the imidate group is stabilized by a hydrogen bond with the indole NH moiety of Trp107 and further Van Der Walls interactions were observed with Leu163, Tyr113, Tyr265 and Asn268 side chains. In the docking pose of GOLD (Fig. S4B), the same imidate stabilization is done by a hydrogen bond/π stacking interaction with the NH moiety of Cys112. Further non-covalent contacts consist in a cation/π stacking interaction between the NH moiety of the ligand and the backbone carbonyl group of Gly164 and the hydroxyl group of Vinagliptin with OH moiety of Tyr274 side chain. On the other hand, considerable modification to the backbone of the protease domain of PLpro were observed as a consequence of Valdagliptin binding.

**Figure S4** Molecular interactions of Vildagliptin with SARS-CoV PLpro and induced fit. The figure shows the molecular interactions of best pose of CovDock (A, green sticks) and GOLD (B, cyan sticks). Van der Walls interactions are shown as yellow lines, hydrogen bonds in red, and π-stacking in magenta. Larger displacements (> 2.0 Å) between the apo-PLpro backbone (white) and Vildagliptin-PLpro complexes after MAB minimizations were observed in the protease domain of PLpro (orange sections).
Comparison against the non-covalent inhibitor of PLpro of SARS-CoV

The studied gliptins share similar non-covalent interactions with the residues reported for a specific potent SARS-CoV inhibitor (PDB ID 4OVZ). Hydrogen bonds, π-π stacking, and Vander Walls interactions were found on Tyr269, the formation of a dipolar interaction occurring on CO moiety of Gly164, and one hydrogen bond between the reported inhibitor and Asp165. Several Van der Walls interactions were observed with residues Pro248, Pro249 Thr302, Gln270, Asp165, Asp265, Tyr274, Thr302 where the most relevant non-covalent interactions occurred between the reported inhibitor and Tyr269.

Interestingly, our results showed similar interactions between the studied gliptins and Tyr269 and other Plpro protease domain residues (Fig. S4). Additionally, the structural alignment after MAB minimization demonstrated that a indicated an adjusted fit shift on similar regions of the Plpro protease domain in comparison which the modifications driven by the binding of Vildagliptin and other proposed gliptins, particularly in the loop comprised by the Asn268, Tyr269, and Gln270.

Figure S5 Molecular interactions of reported non covalent inhibitor with SARS-CoV PLpro and induced fit. The ligand is shown as magenta sticks. Van der Walls interactions are shown as yellow lines, hydrogen bonds in red, and π- π in orange, and dipolar interaction in cyan. Larger displacements (> 2.0 Å) between the apo-PLpro backbone (white cartoons) and inhibitor-PLpro complex after MAB force field minimizations were observed in the protease domain of PLpro (orange sections)

References


